2019 ASCO GU Symposium

2019 ASCO GU Symposium

INTERVIEW WITH DENA BATTLE
Patient Perspectives on Cytoreductive Nephrectomy after the CARMENA Trial

VIEW ALL ASCO GU 2019 VIDEOS

Prostate Cancer Foundation 2018 Scientific Retreat

Prostate Cancer Foundation 2018 Scientific Retreat

INTERVIEW WITH OLIVER SARTOR
Overall Survival Benefit and Racial Disparities in African American Men with Metastatic Prostate Cancer

VIEW ALL PCF VIDEOS

2019 ASCO GU Symposium

2019 ASCO GU Symposium

INTERVIEW WITH KARIM FIZAZI
ARAMIS - Efficacy and Safety of Darolutamide in nmCRPC

VIEW ALL ASCO GU 2019 VIDEOS

2019 ASCO GU Symposium

2019 ASCO GU Symposium

INTERVIEW WITH JAMES GULLEY
Immunotherapy Across Genitourinary Malignancies

VIEW ALL ASCO GU 2019 VIDEOS

Featured Videos

#AUA14 - Cryo Online Data Registry Outcomes: Minimum five year follow up data - Session Highlights

ORLANDO, FL USA (UroToday.com) - This study group used the Cryo Online Data (COLD) registry to report 5year outcomes for patients who underwent primary cryoablation of the whole prostate.

The authors risk stratified a total of 1 111 patients who were never treated by prostate cryoablation. Five-year biochemical progression of the patients who were treated by cryoablation for the first time was analyzed using Kaplan Meier method.

auaFor low-, intermediate-, and high-risk patients, the authors found that biochemical progression-free survival rate was 79.9%, 64.1%, and 68.1%, respectively. For patients with PSA of less than 0.4, progression-free survival was 91%, 80.5%, and 77.6%, respectively. For those patients with PSA greater than 0.4, authors found that the 24-hour progression rates were higher than 34%. Continence was preserved for over 90% of patients. Authors also found that 5.9% of patients had urinary retention while 0.5% developed rectal fistula. Thirty-five percent of patients remained potent at 12 months after cryoablation.

The authors concluded that cryoablation therapy produces similar outcomes to surgical and radiation outcomes, regardless of which risk group they are placed in. They also conclude that PSA of above 0.4 is a predictor of biochemical progression in patients treated by whole prostate cryoablation. Therefore, it is necessary to follow these patients more closely to prevent advancing disease.

There are limitations to the study, including its retrospective nature. It may be useful to include other variables into the model in order to assess the real predictive value of PSA of above 0.4. Given there might be confounding variables that might have been omitted, the results will be more powerful if these are included in future analysis.

Presented by David Levy, MD at the American Urological Association (AUA) Annual Meeting - May 16 - 21, 2014 - Orlando, Florida USA

Cleveland Clinic, Cleveland, OH USA

Written by Garen Abedi, MD, University of California (Irvine), and medical writer for UroToday.com

 

Conference Coverage
 
Recent data from conferences worldwide
Journals
Publications focusing on urologic cancer treatments through original manuscripts
Everyday Urology Volume 3 Issue 4

Everyday Urology™ - Oncology Insights

PCAN cover

Prostate Cancer and Prostatic Diseases

From the Editor

E-Newsletters

Newsletter subscription

Free Daily and Weekly newsletters offered by content of interest

The fields of GU Oncology and Urology are rapidly advancing. Sign up today for articles, videos, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.

Subscribe